Expert Perspectives on EVRIANCE clinical trial data

EP: 1.Data Review of the Efficacy and Safety of Vismodegib in Advanced Basal Cell Carcinoma (EVRIANCE Trial)

Now Viewing

EP: 2.Expert Perspectives on EVRIANCE clinical trial data

EP: 3.Data Review of 2 doses of Sonidegib in Advanced Basal Cell Carcinoma (BOLT Trial)

EP: 4.Expert Perspectives on BOLT clinical trial data

Jonathan S Zager, MD, FACS, FSSO

Moffitt Cancer Center

Tampa, Florida

Lilia Correa-Selm, MD, FAAD, FACMS

Moffitt Cancer Center

Tampa, Florida

Aaron Farberg, MD

Bare Dermatology

Dallas, Texas

John Strasswimmer, MD, PhD

Florida Atlantic University

Delray Beach, Florida

Andrew Weinstein, MD, MPH, FAAD

Boynton Beach Skin, University of Miami

Boynton Beach and Coral Gables, Florida

Series Description: Experts in dermatology discuss the clinical trial data from the BOLT and EVRIANCE clinical trials and review patient cases related to the management of patients with locally advanced basal cell carcinoma treated with sonidegib and vismodegib.

Segment Description: Andrew Weinstein, MD, MPH, FAAD and Jonathan S Zager, MD, FACS, FSSO explore the potential rationale behind observed variations in the and GLI and PTCH expression data within the EVRAINCE trial and comment on potential factors contributing to bias within the study.